Viewing nowNeurica Capsule 150mg (Pregabalin)
Pregabalin 150mg
Hard capsule · Prescription medication
NexPharm Korea Co., Ltd.

MFDS item code 201603622 · Approved 2016.06.20 · Insurance code 662503650
Treatment of neuropathic pain and fibromyalgia, adjunctive treatment of partial-onset epileptic seizures
This medication is used to treat peripheral and central neuropathic pain in adults. It is also used as an adjunct therapy for partial seizures in patients with epilepsy, regardless of the presence of secondary generalized symptoms. Additionally, it is effective in alleviating symptoms of fibromyalgia. It helps improve the discomfort of patients by addressing a variety of neuromuscular-related disorders.
This medicine is administered orally as pregabalin, with the total daily dose divided into 2 doses, regardless of food. Since this medicine is primarily excreted by the kidneys, the dosage should be adjusted in patients with impaired renal function. (See section ‘5. Patients with renal impairment’) 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on each patient's response and tolerability, the dose may be increased to 300 mg/day after 3 to 7 days. If necessary, the dose may subsequently be increased at 7-day intervals to a maximum of 600 mg/day. 2) Central neuropathic pain Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on each patient's response and tolerability, the dose may be increased to 300 mg/day after 1 week. After an additional 1 week, the dose may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, a dose reduction may be considered. (See section ‘4. Discontinuation of treatment’) 2. Epilepsy Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on each patient's response and tolerability, the dose may be increased to 300 mg/day after 1 week. If necessary, the dose may subsequently be increased at 7-day intervals to a maximum of 600 mg/day. 3. Fibromyalgia The recommended dose of this medicine for fibromyalgia is 300 mg ~ 450 mg/day. The initial dose is 75 mg twice daily (150 mg/day), and based on efficacy and tolerability, it may be increased to 150 mg twice daily (300 mg/day) within 1 week. For patients who do not experience sufficient benefit at a dose of 300 mg/day, the dose may be increased to 225 mg twice daily (450 mg/day) within 1 week. Clinical studies have also been conducted at a dose of 600 mg/day; however, there is no evidence of additional benefit or adequate tolerability at this dose. Considering the dose-dependent adverse reactions, doses exceeding 450 mg/day are not recommended. 4. Discontinuation of treatment Based on current clinical experience, when discontinuing this medicine, it should be tapered gradually over at least 1 week. 5. Patients with renal impairment This medicine is effectively removed from plasma by hemodialysis. (Approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, a supplemental dose should be administered promptly after each 4-hour hemodialysis session. [Table 1]. Pregabalin dosage based on renal function Creatinine clearance (CLcr), (mL/min) ≥60: Initial dose 150 (mg/day), maximum dose 600 (mg/day), BID or TID Creatinine clearance (CLcr), (mL/min) ≥30 -<60: Initial dose 75 (mg/day), maximum dose 300 (mg/day), BID or TID Creatinine clearance (CLcr), (mL/min) ≥15 -<30: Initial dose 25-50 (mg/day), maximum dose 150 (mg/day), QD or BID Creatinine clearance (CLcr), (mL/min) <15: Initial dose 25 (mg/day), maximum dose 75 (mg/day), QD Supplemental dose after hemodialysis: Initial dose 25, maximum dose 100, single dose b TID = total daily dose administered in 3 divided doses BID = total daily dose administered in 2 divided doses QD = administered once daily a: The total daily dose (mg/day) should be administered in divided doses as specified in the dosing regimen. b: The supplemental dose refers to a dose administered as a single additional dose. 6. Patients with hepatic impairment No dosage adjustment is necessary in patients with hepatic impairment. 8. Older adults (65 years of age or older) In older adults with impaired renal function, a dose reduction may be necessary.
Children under 12 years of age: Administration is not recommended because there are insufficient data on safety and efficacy. Adolescent patients aged 12 to 17 years: Administration is not recommended because there are insufficient data on safety and efficacy.
This medication may increase the risk of suicidal thoughts or behaviors, so any mood changes or unusual behaviors that occur during treatment should be reported to a healthcare professional immediately. Those with an allergy to pregabalin or any ingredients in this medication should not take it. Patients with lactose intolerance or certain genetic metabolic disorders should not take this medication. Diabetic patients may experience weight gain after taking this medication, necessitating adjustments to their blood glucose control medication doses. If hypersensitivity reactions such as angioedema occur, the use of this medication should be immediately discontinued. Elderly patients may experience increased dizziness or drowsiness when taking this medication, so caution is advised, as there is a risk of falls. Vision may become blurred or there may be changes in eyesight; if these symptoms occur, consultation with a doctor is recommended. Sudden discontinuation of this medication may lead to withdrawal symptoms such as insomnia, headaches, and anxiety, so it should be gradually reduced according to a doctor's instructions. There is a risk of drug abuse associated with this medication, so patients with a history of substance abuse should exercise special caution and report any unusual behaviors to healthcare professionals. Patients with impaired kidney function should have their dosage adjusted and should follow their doctor's instructions. Caution is required for patients with heart disease when taking this medication. The concurrent use of this medication with opioid analgesics may enhance central nervous system depressant effects, so caution is warranted. Patients with respiratory or neurological disorders, kidney impairments, or the elderly may have a heightened risk of severe respiratory depression and may require dosage adjustments. In early pregnancy, taking this medication may pose risks to the fetus, so pregnant women should not use it, and women of childbearing potential should employ effective contraception while using this medication. Women who are breastfeeding should consider stopping breastfeeding or ceasing the medication, as it may be passed through breast milk and affect the infant. When engaging in activities that require alertness, such as driving or operating machinery, caution is advised as dizziness or drowsiness may occur after taking this medication. If symptoms such as skin rash, fever, or swelling around the lips or eyes develop while taking this medication, it should be discontinued immediately and a doctor consulted. In case of overdose, symptoms may include drowsiness, confusion, depression, and seizures, and blood dialysis may be required if necessary. This medication should be kept out of the reach of children and should not be transferred to other containers.
Not everyone experiences these, and they can vary from person to person.
This medication may be sensitive to air or moisture, and should be stored in a tightly closed container. For safe use, it is advised to keep it at room temperature between 15°C and 30°C.
A white hard capsule containing white powder that is white or light yellow in color.
30 capsules/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowPregabalin 150mg
Hard capsule · Prescription medication
NexPharm Korea Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 300mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Hanmi Pharm. Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Hanmi Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.